New Fentanyl Sublingual Spray Launched: Where to Find Advice and Solutions for the Ongoing Threat of Adverse Effects from Fentanyl

Share Article

As published on March 27th, 2012 in the Pharmaceutical Business Review, Insys Therapeutics launched Subsys (Fentanyl sublingual spray) for the management of persistent cancer pain. Fentanyl is a potent synthetic narcotic analgesic used to treat breakthrough cancer pain and is commonly used in pre-procedures as a pain reliever as well as an anesthetic. On September 2nd 2011, the widower of a New York woman, Steven Shemelia filed a lawsuit (case no. 2:2011cv05559) at the Philadelphia Court of Common Pleas, claiming that his wife, Patricia Shemelia, died as a result of using a Mylan Fentanyl patch. In October 2010, Actavis Inc. announced a voluntary recall of 18 lots of Fentanyl Transdermal System due to possible injury of active ingredients being released too fast. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Fentanyl severe adverse events [http://www.attorneyone.com/fentanyl/ .

Fentanyl severe adverse events threat

Fentanyl severe adverse events threat

Recall of 18 lots of Fentanyl Transdermal System due to possible injury

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Fentanyl severe adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

Insys Therapeutics launched Subsys (Fentanyl sublingual spray) for the management of persistent cancer pain, as published on March 27th, 2012 in the Pharmaceutical Business Review. Fentanyl is the generic name for an extremely potent synthetic narcotic drug for cancer patients and is commonly used in pre-procedures as a pain reliever as well as an anesthetic. In October 2010, Actavis Inc. announced a voluntary Fentanyl Recall of 18 lots of Fentanyl Transdermal System due to possible injury of active ingredients being released too fast.

According to court documents, on September 2nd 2011, the widower of a New York woman, Steven Shemelia filed a lawsuit (case no. 2:2011cv05559) at the Philadelphia Court of Common Pleas against Mylan, Inc., claiming that his wife, Patricia Shemelia, died as a result of using a Mylan Fentanyl patch. As mentioned in the lawsuit, Fentanyl is a painkiller at least “80 times more potent than morphine”.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of in case of Fentanyl severe adverse events, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat of severe adverse events from Fentanyl remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

After receiving reports of at least 120 deaths, the FDA issued in July 2005 the first warning on the risk of fentanyl patch overdose. In December 2007 the FDA issued the second warning stressing that the patch should only be prescribed to people who take regular and daily narcotic pain medication to deal with chronic pain.

AttorneyOne.com has further information on Fentanyl lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Fentanyl at our website. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/4/prweb9380678.htm.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sean Burke
Attorney One
1-877-230-7343
Email >
Visit website